Should a patient discontinue Mycophenolate mofetil before, after, or not at all for a cerebrospinal fluid (CSF) leak repair using a fibrin glue patch?

Should Mycophenolate Be Stopped for CSF Leak Fibrin Glue Patch?

For a CSF leak repair with fibrin glue patch, mycophenolate should be held for 1 week prior to the procedure in most patients, based on perioperative immunosuppression guidelines for elective surgery.

Rationale and Evidence-Based Approach

The 2022 ACR/AAHKS guideline for perioperative management of antirheumatic medications provides the most relevant framework, recommending withholding mycophenolate mofetil 1 week prior to elective surgery in patients with non-severe SLE 1. While this guideline specifically addresses joint arthroplasty, the principles apply to other surgical procedures requiring tissue healing and infection risk mitigation.

Key Decision Points:

For Standard Risk Patients:

• Hold mycophenolate 1 week before the procedure 1
• This allows clearance of the drug (half-life ~18 hours) and partial immune system recovery
• Resume after adequate wound healing is confirmed (typically 1-2 weeks post-procedure)

For High-Risk Patients (severe SLE with organ involvement):

• Consider continuing mycophenolate through the procedure 1
• This applies only if the patient has active severe disease with risk of organ damage from flare
• Requires shared decision-making with the patient's rheumatologist
• The guideline notes that patients stable for >6 months may still discontinue medications perioperatively 1

Important Caveats:

Infection Risk Considerations: The FDA label emphasizes that mycophenolate increases susceptibility to bacterial, fungal, and viral infections, which can be serious or fatal 2. CSF leak repairs carry inherent infection risk (meningitis), making temporary immunosuppression reduction prudent. The drug label specifically warns about oversuppression of the immune system with combination immunosuppressant therapy 2.

Neutropenia Monitoring: If the patient develops neutropenia (ANC < 1.3 x 10³/µL), mycophenolate should be interrupted or dose-reduced regardless of surgical timing 2. Check CBC before proceeding with any planned hold.

Disease Stability Assessment:

• Patients with frequent flares or difficult-to-control disease may need to continue therapy 1
• Those stable for >6 months are better candidates for temporary discontinuation 1
• Coordinate with the prescribing rheumatologist before making changes

Procedure-Specific Context:

Fibrin glue CSF leak repairs have high success rates (75-96%) 3, 4, 5 and are minimally invasive compared to open surgery. The procedure itself does not require immunosuppression, and adequate healing of the dural defect is critical to prevent recurrence and meningitis. This supports the rationale for temporary mycophenolate withdrawal to optimize healing conditions.

Practical Algorithm:

1. Assess disease severity: Is this severe SLE with organ involvement requiring continuous immunosuppression?

   • If NO → Hold mycophenolate 1 week before procedure
   • If YES → Consult rheumatology; consider continuing if unstable disease

2. Check baseline CBC: Is ANC > 1.3 x 10³/µL?

   • If NO → Address neutropenia before elective procedure
   • If YES → Proceed with planned hold

3. Evaluate disease stability: Has patient been stable >6 months without flares?

   • If YES → Stronger indication to hold medication
   • If NO → More cautious approach; closer rheumatology involvement

4. Post-procedure: Resume mycophenolate once adequate healing confirmed (typically 1-2 weeks) and no signs of infection

The default approach for most patients undergoing CSF leak repair should be to hold mycophenolate for 1 week pre-procedure, with exceptions only for those with severe, unstable disease requiring continuous immunosuppression.